In 2012, Heppner's lab reported in Nature Medicine that blocking IL-12 and IL-23 significantly reduced Alzheimer's-related brain changes in mice. "But we couldn't unravel the underlying mechanism ...

The decision to start the ICONIC-ASCEND study of icotrokinra versus IL-12 and IL-23 inhibitor Stelara (ustekinumab) comes on the back of the placebo-controlled phase 3 ICONIC-LEAD study ...

with other rivals including Johnson & Johnson’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) and Takeda Pharma’s α4β7 inhibitor Entyvio (vedolizumab), both of which are approved for both ...

The study, published in The Journal of ImmunoTherapy of Cancer, details how an immunoprotected device near the tumor microenvironment containing cells engineered to locally release interleukin-12 ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...